ClinicalTrials.gg
CompletedNCT05339828Updated Oct 27, 2022

Unroofing Curettage for Pilonidal Disease

An observational study in Pilonidal Disease, Recurrence and Healing Wound, sponsored by Ankara Diskapi Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-27.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Ankara Diskapi Training and Research Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
203
Ages
18 Years and older
Sex
All
01

Study summary

This study aimed to investigate the outcomes of patients who underwent UC as the primary intervention for simple or complex SPD

Read the detailed description

Sacrococcygeal pilonidal disease (SPD) is a well-known chronic inflammatory condition that affects young adults; There are many treatment options available today, from simple non-surgical methods to extensive flap procedures. However, elaborate treatment strategies can turn this easily treatable disease into a long-term surgical ordeal, causing complications worse than the primary disease itself.

While, UC is considered safe and effective for treating simple SPD, its suitability for treating complex disease is poor and controversial. To date, no studies have investigated the efficacy of UC specifically when treating complex SPD.

This is the first study to identify and compare efficacy and outcomes after UC in patients classified into simple and complex SPD groups.

This study was conducted at the Department of Surgery of the Diskapi Training and Research Hospital in Ankara, Turkey. The local ethics committee of the institution approved the study protocol (number 27/02, dated March 22, 2016), and written informed consent was obtained from all participants.

02

Conditions studied

  • Pilonidal Disease
  • Recurrence
  • Healing Wound

Browse trials for

Keywords

  • complex pilonidal disease
  • unroofing curettage
  • recurrence
  • Lay open technique
03

In context

Lead sponsor

Ankara Diskapi Training and Research Hospital is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Consecutive patients aged 18 years or older who applied for simple and complex SPD treatment between April 2016 and September 2018 and preferred the UC surgery from all the treatment options offered by the physician.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consecutive patients aged 18 years or older

Exclusion criteria

Exclusion Criteria:

  • acute pilonidal abscess
  • poorly controlled
  • diabetes mellitus,
  • or coagulation disorders,
  • pregnancy and/or lactation,
  • other acute surgical diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
203 participants (actual)
Patient registry
No

Groups and cohorts

  • unroofing curettage

    Surgery was performed with the patient lying in the prone position under local anesthesia. Next, a local anesthetic agent comprising a solution of lidocaine (20 mg/mL) and adrenaline (0.0125 mg/mL) was diluted with distilled water in a 1:2 ratio and applied. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing.

    Procedure: unroofing curettage

Interventions

  • Procedureunroofing curettage

    Surgery was performed with the patient lying in the prone position under local anesthesia. The tract was identified by passing small artery forceps along its length and was then opened by cutting directly down onto the forceps. The sinus and all its tracts were completely unroofed, and the base was curetted to remove all necrotic content, hair, and granulation tissue using a dry gauze. The fibrotic back wall was left as intact as possible to avoid delayed healing. Hemostasis was achieved using diathermy with no drainage needed.

06

What researchers measure

Primary outcomes

  1. Recurrence

    After healing was complete, any new sinus orifice or discharge from the wound was defined as disease recurrence.

    Time frame: 15 days

Secondary outcomes

  1. complete healing time

    time after surgery until the wound is completely epithelialized

    Time frame: 15 days

  2. VAS pain score

    Visual analog scale for pain

    Time frame: 15 days

  3. time to return to daily activities

    time after surgery until the to return to daily activities

    Time frame: 15 days

07

Study locations

1 site
  • Ankara Diskapi Training and Research Hospital
    Ankara, 06110, Turkey
08

References and documents

Publications

  • Kepenekci I, Demirkan A, Celasin H, Gecim IE. Unroofing and curettage for the treatment of acute and chronic pilonidal disease. World J Surg. 2010 Jan;34(1):153-7. doi: 10.1007/s00268-009-0245-6. PubMed 19820992 ↗
  • McCallum IJ, King PM, Bruce J. Healing by primary closure versus open healing after surgery for pilonidal sinus: systematic review and meta-analysis. BMJ. 2008 Apr 19;336(7649):868-71. doi: 10.1136/bmj.39517.808160.BE. Epub 2008 Apr 7. PubMed 18390914 ↗
  • Karakayali F, Karagulle E, Karabulut Z, Oksuz E, Moray G, Haberal M. Unroofing and marsupialization vs. rhomboid excision and Limberg flap in pilonidal disease: a prospective, randomized, clinical trial. Dis Colon Rectum. 2009 Mar;52(3):496-502. doi: 10.1007/DCR.0b013e31819a3ec0. PubMed 19333052 ↗
  • Olcucuoglu E, Sahin A. Unroofing curettage for treatment of simple and complex sacrococcygeal pilonidal disease. Ann Surg Treat Res. 2022 Oct;103(4):244-251. doi: 10.4174/astr.2022.103.4.244. Epub 2022 Oct 7. PubMed 36304191 ↗

Individual participant data

Plan to share: No — Nothing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in May 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2022
First posted
Apr 21, 2022
StartActual
Apr 27, 2022
Primary completionActual
May 2, 2022
CompletionActual
May 5, 2022
Last update
Oct 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05339828
Lead sponsor
Ankara Diskapi Training and Research Hospital
Responsible party
Alpaslan Şahin (Principal Investigator, Diskapi Yildirim Beyazit Education and Research Hospital) — Principal investigator
First posted
Apr 21, 2022
Start date
Apr 27, 2022
Primary completion
May 2, 2022
Completion
May 5, 2022
Last update
Oct 27, 2022

Study contacts

Engin Olcucuoglu, MD
principal investigator · Ankara Diskapi Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion